Functional polymorphism of the myeloperoxidase gene (G-463A) in depressive patients

Acta Neuropsychiatrica

Volumn 22, Issue 5, 2010, Pages 218-222

  Gałecki, Piotr ^a   Florkowski, Antoni ^a   Bobińska, Kinga ^a   Śmigielski, Janusz ^a   Bieńkiewicz, Małgorzata ^a   Szemraj, Janusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

depression; gene polymorphism; myeloperoxidase

Indexed keywords

MYELOPEROXIDASE;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; G 463A GENE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77956519695     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2010.00483.x     Document Type: Article

References (53)

1. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006 27: 24 31.
2. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 1995 19: 11 38.
3. Leonard BE. Inflammation, depression and dementia: are they connected?. Neurochem Res 2007 32: 1749 1756.
4. Nauseef WM. Contribution of myeloperoxidase to proinflammatory events: more than an antimicrobial system. Int J Hematol 2001 74: 125 133.
5. Yap YW, Whiteman M, Cheung NS. Chlorinative stress: an under appreciated mediator of neurodegeneration? Cell Signal 2007 19: 219 228.
6. Green PS, Mendez AJ, Jacob JS et al. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. J Neurochem 2004 90: 724 733.
7. Hansson M, Olsson I, Nauseef WM. Biosynthesis, processing, and sorting of human myeloperoxidase. Arch Biochem Biophys 2006 445: 214 224.
8. Malle E, Furtmüller PG, Sattler W, Obinger C. Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007 152: 838 854.
9. Spickett CM, Jerlich A, Panasenko OM et al. The reactions of hypochlorous acid, the reactive oxygen species produced by myeloperoxidase, with lipids. Acta Biochim Pol 2000 47: 889 899.
10. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003 8: 365 370.
11. Lucca G, Comim CM, Valvassori SS et al. Effects of chronic mild stress on the oxidative parameters in the rat brain. Neurochem Int 2009 54: 358 362.
12. Yanik M, Erel O, Kati M. The relationship between potency of oxidative stress and severity of depression. Acta Neuropsychiatry 2004 16: 200 203.
13. Monkul ES, Malhi GS, Soares JC. Mood disorders-review of structural MRI studies. Acta Neuropsychiatry 2003 15: 368 380.
14. Bachis A, Cruz MI, Nosheny RL, Mocchetti I. Chronic unpredictable stress promotes neuronal apoptosis in the cerebral cortex. Neurosci Lett 2008 442: 104 108.
15. Lefkowitz DL, Lefkowitz SS. Microglia and myeloperoxidase: a deadly partnership in neurodegenerative disease. Free Radic Biol Med 2008 45: 726 731.
16. Ekdahl CT, Claasen JH, Bonde S, Kokaia Z, Lindvall O. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003 100: 13632 13637.
17. Xu H, Chen Z, He J et al. Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006 16: 551 559.
18. Leonard BE. The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2001 25: 767 780.
19. Maes M, Smith RS. Fatty acid, cytokines, and major depression. Biol Psychiatry 1998 43: 313 314.
20. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acids levels in red blood cells membranes of depressive patients. Biol Psychiatry 1998 43: 315 319. (Pubitemid 28137622)
21. Tomàs C, Cañellas F, Rodríguez V et al. Genetic linkage study for bipolar disorders on chromosomes 17 and 18 in families with a high expression of mental illness from the Balearic Islands. Psychiatr Genet 2006 16: 145 151.
22. Piedrafita FJ, Molander RB, Vansant G, Orlova EA, Pfahl M, Reynolds WF. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996 271: 14412 14420.
23. Hoy A, Trégouët D, Leininger-Muller B et al. Serum myeloperoxidase concentration in a healthy population: biological variations, familial resemblance and new genetic polymorphisms. Eur J Hum Genet 2001 9: 780 786.
24. Hoy A, Leininger-Muller B, Kutter D, Siest G, Visvikis S. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002 40: 2 8.
25. Vaccarino V, Brennan ML, Miller AH et al. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry 2008 64: 476 483.
26. ICD 10. The international statistical classification of diseases and related health problems, 10th revision. Geneva: WHO, 1992.
27. Bland JM, Altman DG. Statistics notes: the odds ratio. BMJ 2000 320: 1468.
28. Shi M, Hu J, Dong X et al. Association of unipolar depression with gene polymorphisms in the serotonergic pathways in Han Chinese. Acta Neuropsychiatry 2008 20: 139 144.
29. Lee HY, Kang RH, Han SW et al. Association of glucocorticoid receptor polymorphisms with the susceptibility to major depressive disorder and treatment responses in Korean depressive patients. Acta Neuropsychiatry 2009 21: 11 17.
30. Hallingbäck HR, Gabdoulline RR, Wade RC. Comparison of the binding and reactivity of plant and mammalian peroxidases to indole derivatives by computational docking. Biochemistry 2006 45: 2940 2950.
31. Crawford FC, Freeman MJ, Schinka JA et al. Association between Alzheimer's disease and a functional polymorphism in the myeloperoxidase gene. Exp Neurol 2001 167: 456 459.
32. Reynolds WF, Rhees J, Maciejewski D et al. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol 1999 155: 31 41.
33. Zappia M, Manna I, Serra P et al. Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. Arch Neurol 2004 61: 341 344.
34. Usui C, Shibata N, Ohnuma T et al. No genetic association between the myeloperoxidase gene-463 polymorphism and estrogen receptor-alpha gene polymorphisms and Japanese sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 2006 21: 296 299.
35. Combarros O, Infante J, Llorca J, Peña N, Fernández-Viadero C, Berciano J. The myeloperoxidase gene in Alzheimer's disease: a case-control study and meta-analysis. Neurosci Lett 2002 326: 33 36.
36. Gohier B, Ferracci L, Surguladze SA et al. Cognitive inhibition and working memory in unipolar depression. J Affect Disord 2009 116: 100 105.
37. Pope SK, Kritchevsky SB, Ambrosone C et al. Myeloperoxidase polymorphism and cognitive decline in older adults in the health, aging, and body composition study. Am J Epidemiol 2006 163: 1084 1090.
38. Manna I, Valentino P, La Russa A et al. Genetic variation in the myeloperoxidase gene and cognitive impairment in multiple sclerosis. J Negat Results Biomed 2006 5: 3.
39. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler 2009 15: 385 392.
40. Kantarci OH, Atkinson EJ, Hebrink DD, McMurray CT, Weinshenker BG. Association of a myeloperoxidase promoter polymorphism with multiple sclerosis. J Neuroimmunol 2000 105: 189 194.
41. Nagra RM, Becher B, Tourtellotte WW et al. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol 1997 78: 97 107.
42. Nikpoor B, Turecki G, Fournier C, Théroux P, Rouleau GA. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 2001 142: 336 339.
43. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003 65: 201 210.
44. McCaffery JM, Frasure-Smith N, Dubé MP et al. Common genetic vulnerability to depressive symptoms and coronary artery disease: a review and development of candidate genes related to inflammation and serotonin. Psychosom Med 2006 68: 187 200.
45. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol 2000 20: 1716 1723.
46. Jun TY, Pae CU, Hoon-Han S et al. Possible association between-G308A tumor necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population. Psychiatr Genet 2003 13: 179 181.
47. Pae CU, Yu HS, Kim TS et al. Monocyte chemoattractant protein-1 (MCP1) promoter-2518 polymorphism may confer a susceptibility to major depressive disorder in the Korean population. Psychiatry Res 2004 127: 279 281.
48. Wong ML, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008 13: 800 812.
49. Sullivan PF. Spurious genetic associations. Biol Psychiatry 2007 61: 1121 1126.
50. Atzeni F, Boiardi L, Casali B et al. Lack of association of the-463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients. Rheumatology (Oxford) 2007 46: 1547 1550.
51. Feyler A, Voho A, Bouchardy C et al. Point: myeloperoxidase-463G-> a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2002 11: 1550 1554.
52. Osterreicher CH, Datz C, Stickel F et al. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J Hepatol 2005 42: 914 919. (Pubitemid 40693209)
53. Rajp A, Adu D, Savage CO. Meta-analysis of myeloperoxidase G-463/A polymorphism in anti-neutrophil cytoplasmic autoantibody-positive vasculitis. Clin Exp Immunol 2007 149: 251 256.